Predicting recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: Development and validation of the JIKEI-YAYOI score
Yuya Iwamoto(Jikei University School of Medicine), Takahiro Kimura(Jikei University School of Medicine), Fumihiko Urabe(Jikei University School of Medicine), Naoki Uchida(SHOWA Medical University), Jun Miki(Jikei University School of Medicine), Yuhei Koike(Jikei University School of Medicine), Kojiro Tashiro(Jikei University School of Medicine), Sounak Gupta(Mayo Clinic), Shuhei Hara(Jikei University School of Medicine), Shunsuke Tsuzuki(Jikei University School of Medicine), Yu Imai(Jikei University School of Medicine), Stephen A. Boorjian(Mayo Clinic), Aaron M. Potretzke(Mayo Clinic), Hirokazu Kagawa(Jikei University School of Medicine), Halle Foss(Medical College of Wisconsin), Keiichiro Miyajima(Jikei University School of Medicine), Kosuke Iwatani(Jikei University Kashiwa hospital), Yudai Ishiyama(Jacksonville University)
Cited by 5
Related Papers
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
|European Urology|2015|688
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management
|The Journal of Urology|2022|462
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy
|Cancer Cell|2021|453
Extracellular vesicles as biomarkers and therapeutic targets for cancer
|American Journal of Physiology-Cell Physiology|2019|412